Modelling and investigation of the CD4<sup>+</sup> T cells-macrophages paradox in melanoma immunotherapies by Eftimie, Raluca & Hamam, Haneen
                                                              
University of Dundee
Modelling and investigation of the CD4+ T cells-macrophages paradox in melanoma
immunotherapies
Eftimie, Raluca; Hamam, Haneen
Published in:
Journal of Theoretical Biology
DOI:
10.1016/j.jtbi.2017.02.022
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Eftimie, R., & Hamam, H. (2017). Modelling and investigation of the CD4+ T cells-macrophages paradox in
melanoma immunotherapies. Journal of Theoretical Biology, 420, 82-104.
https://doi.org/10.1016/j.jtbi.2017.02.022
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Contents lists available at ScienceDirect
Journal of Theoretical Biology
journal homepage: www.elsevier.com/locate/yjtbi
Modelling and investigation of the CD4+ T cells – Macrophages paradox in
melanoma immunotherapies
Raluca Eftimie⁎, Haneen Hamam
Division of Mathematics, University of Dundee, Dundee DD1 4HN, United Kingdom
A R T I C L E I N F O
MSC:
92C50
34A34
Keywords:
M1 and M2 macrophages
Th1 and Th2 immune cells
B16 melanoma
Mathematical approach
A B S T R A C T
It is generally accepted that tumour cells can be eliminated by M1 anti-tumour macrophages and CD8+ T cells.
However, experimental results over the past 10–15 years have shown that B16 mouse melanoma cells can be
eliminated by the CD4+ T cells alone (either Th1 or Th2 sub-types), in the absence of CD8+ T cells. In some
studies, elimination of B16 melanoma was associated with a Th1 immune response (i.e., elimination occurred in
the presence of cytokines produced by Th1 cells), while in other studies melanoma elimination was associated
with a Th2 immune response (i.e., elimination occurred in the presence of cytokines produced by Th2 cells).
Moreover, macrophages have been shown to be present inside the tumours, during both Th1 and Th2 immune
responses. To investigate the possible biological mechanisms behind these apparently contradictory results, we
develop a class of mathematical models for the dynamics of Th1 and Th2 cells, and M1 and M2 macrophages in
the presence/absence of tumour cells. Using this mathematical model, we show that depending on the re-
polarisation rates between M1 and M2 macrophages, we obtain tumour elimination in the presence of a type-I
immune response (i.e., more Th1 and M1 cells, compared to the Th2 and M2 cells), or in the presence of a type-
II immune response (i.e., more Th2 and M2 cells). Moreover, tumour elimination is also possible in the
presence of a mixed type-I/type-II immune response. Tumour growth always occurs in the presence of a type-II
immune response, as observed experimentally. Finally, tumour dormancy is the result of a delicate balance
between the pro-tumour eﬀects of M2 cells and the anti-tumour eﬀects of M1 and Th1 cells.
1. Introduction
The anti-tumour role of the immune system has been documented
for at least a century, with one of the earliest studies on the role of
immune surveillance against transformed cells being published by
Ehrich (1909). The last 20–30 years have seen a very rapid increase in
the number of experimental studies that investigate the molecular and
cellular mechanisms behind the tumour-immune interactions.
However, in many cases, the experimental results are contradictory.
For example, Mattes et al. (2003) investigated the anti-tumour eﬀects
of two types of CD4+ T cells (Th1 and Th2 cells) on B16 melanoma, and
concluded that contrary to the generally accepted idea that the CD4+ T
cells have only a helper role, they can actually eliminate tumours on
their own via the cytokines they produce. Moreover, the authors
showed that while the Th1-tumour interactions led to temporary
tumour control followed by tumour escape and growth (see
Fig. 1(a)), the Th2-tumour interactions led in the long term to tumour
elimination (see Fig. 1(a)). In fact, Mattes et al. (2003) suggested that
tumour elimination in the presence of Th2 cells is helped by the inﬂux
of eosinophils to the tumour site. In addition to eosinophils, the
authors also showed the presence of tumour-inﬁltrating macrophages
(see Fig. 1(b)), which seemed to be associated with tumour growth (but
the authors did not investigate the possible anti-tumour/pro-tumour
action of these macrophages). In a later study, Xie et al. (2010) showed
that the Th1 cells can actually eliminate B16 melanoma cells (see
Fig. 2(a)). Kobayashi et al. (1998) showed that the growth of B16F10
cells is associated with a large number of Th2 cells and a high
concentration of IL-4 cytokines (see Fig. 2(b)). Moreover, Chen et al.
(2011) showed that the growth of B16 melanoma cells is associated
with a shift from anti-tumour M1 macrophages to pro-tumour M2
macrophages (see Fig. 2(c)). (Note that the classiﬁcation of macro-
phages into M1 and M2 phenotypes mirrors the Th1 and Th2
nomenclature (Mantovani et al., 2008), and despite this strict classi-
ﬁcation there is actually a continuum of phenotypes between the M1
and M2 extremes).
The anti-tumour eﬀects of Th1 and Th2 cells are exerted by the
cytokines they produce: (i) the Th1 cells produce type-I cytokines, such
as IFN γ− , IL−2, TNF α− and TNF β− (Magombedze et al., 2014; Lucey
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Fig. 1. Data approximated and re-drawn from Mattes et al. (2003), where the authors transfer Th1 cells or Th2 cells into C57BL/6 mice that were previously injected with B16-OVA
melanoma cells. a) Number of tumour metastases after the adoptive transfer of Th1 cells, Th2 cells and for the control case (i.e. no treatment with immune cells). b) Number of tumour-
inﬁltrating macrophages following the adoptive transfer of Th1 cells and Th2 cells, and comparison with the number of macrophages in control tumours (with no adoptive transfer of
Th1/Th2 cells).
(a)
(b)
(c)
<10<50 <30
no
rm
al
 &
 tu
m
ou
r −
 b
ea
rin
g 
m
ic
e 
(d
ay
 1
4)
C
yt
ok
in
e 
le
ve
l (
pg
/m
l) 
in
IN
F−
ga
m
m
a 
le
ve
ls
 (p
g/
m
l) 
on
 d
ay
 7
N
br
 o
f t
um
ou
r m
et
as
ta
se
s o
n 
da
y 
14
Tu
m
ou
r s
iz
e 
(m
m
2)
(i) (ii)
(ii)
(i)
(i)
(ii)
Fig. 2. (a) Data approximated and re-drawn from Xie et al. (2010), where the authors inject RAG−/− mice (which do not have any CD8+ T cells, B cells or NKT cells) with B16F10
melanoma cells. Panel (i) shows tumour size on day 20 for mice injected with CD4+ T cells and for control mice (with no injection of CD4+ T cells); Panel (ii) shows the level of IFN-γ in
mice injected with CD4+ T cells and in control mice, suggesting that the CD4+ T cells that reduce the size of the tumour are actually Th1 cells (which produce high levels of IFN-γ). (b)
Data approximated and re-drawn from Kobayashi et al. (1998), where the authors inject C57BL/6 mice with B16F10 melanoma cells. Panel (i) shows the number of metastatic colonies
on day 14 after injection; Panel (ii) shows the level of IL −2 IFN-γ and IL −4 cytokines produced by naive CD4+ T cells in normal mice and in mice injected with B16F10 cells. (c) Data
approximated and re-drawn from Chen et al. (2011), where the authors inject C57BL/6 mice with B16F10 melanoma cells. Panel (i) shows tumour volume on days 7 and 12 after
transfer of tumour cells; Panel (ii) shows the percentage of M1 and M2 macrophages inside the tumour, on days 7 and 14.
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et al., 1996); (ii) the Th2 cells produce type-II cytokines, such as IL−4,
IL−5, IL−6, IL−10 and IL−13 Romagnani (1999); Lucey et al. (1996). It
is usually thought that the type-I cytokines (e.g., IFN-γ, IL−2) have an
anti-tumour role (Lucey et al., 1996), while the type-II cytokines (e.g.,
IL−10) are generally associated with tumour growth (Lucey et al.,
1996). These cytokines are not only produced by the Th1/Th2 cells, but
also by other cells in the environment: e.g., macrophages, neutrophils,
eosinophils, etc. (Lucey et al., 1996). In particular, the macrophages
can produce, and respond to, both type-I and type-II cytokines.
Classically activated M1 macrophages are induced by cytokines such
as IFN γ− or TNF α− (Mantovani et al., 2008). Alternatively activated
M2 macrophages are induced by cytokines such as IL−4 and IL−13
(Mantovani et al., 2008). Moreover, the M1 cells are associated with
Th1 responses, being involved in resistance against tumours
(Mantovani et al., 2008). On the other hand, the M2 cells are associated
with Th2 responses, being involved in tumour progression, tissue
repair and remodelling (Mantovani et al., 2008). We emphasise here
the crosstalk between the Th cells and macrophages via the type-I and
type-II cytokines, which might inﬂuence the tumour microenvironment
(see also Fig. 3).
The goal of this study is to derive a class of mathematical models
that can propose hypotheses regarding the apparent paradoxical results
in the anti-tumour eﬀects of Th1 and Th2 cells, and M1 and M2
macrophages. We note that in the mathematical literature there are
various models investigating diﬀerent aspects of the interactions
between Th1 and Th2 cells, and between M1 and M2 macrophages.
For example, the Th1-Th2 dynamics was investigated in the context of
cell diﬀerentiation and cross-regulation (Yates et al., 2000; Bergmann
et al., 2001; Fishman and Perelson, 1999), during the immune
response to allergens (Gross et al., 2011) and asthma development
(Kim et al., 2013), during autoimmune diseases (Louzoun et al., 2001),
following T cell vaccination (Severins et al., 2008), during bacterial
infection in ruminants (Magombedze et al., 2014), or in the rejection of
cancers such as melanoma (Eftimie et al., 2010; Kogan et al., 2013).
The M1-M2 dynamics was investigated during macrophage activation
post-myocardian infarction (Wang et al., 2012), during wound healing
(Yu, 2014), or in the rejection of pancreatic cancer (Louzoun et al.,
2014). However, very few mathematical models investigate the inter-
play between M1/M2 macrophages and Th1/Th2 cells during cancer
evolution (den Breems and Eftimie, 2016). For example, the study in
den Breems and Eftimie (2016) investigated (numerically and with the
help of sensitivity analysis) the inﬂuence of the ratio of M1 and M2
macrophages on early and advanced tumour growth, for normal and
mutated tumour cells. The authors showed that their model can only
exhibit tumour growth (i.e., no tumour elimination). Moreover, they
showed that while a ratio of M2:M1>1 can always predict growth
towards tumour carrying capacity, a ratio of M2:M1<1 can lead to
either growth towards carrying capacity or growth towards a lower
tumour size.
In this study, we will investigate the possible mechanisms that
could explain the elimination of B16 melanoma by Th2 cells in Mattes
et al. (2003) and by Th1 cells in Xie et al. (2010), and the role played by
M1 and M2 macrophages in tumour growth and elimination (given the
crosstalk between Th1/Th2 cells and M1/M2 cells via the cytokines
they produce; see Fig. 3). To this end we develop two mathematical
models: (i) a model for the interactions between the Th cells and
macrophages alone, which is used to investigate the type-I and type-II
immune responses they generate (where we deﬁne a type-I immune
response to be the response dominated by Th1 and M1 cells, and a
type-II immune response to be the response dominated by Th2 and M2
cells); (ii) a model for the interactions between tumour cells, Th cells
and macrophages. We show that tumour can be eliminated both in the
presence of a type-I immune response and a type-II immune response.
Tumour growth is always associated with the presence of a type-II
immune response.
The structure of this article is as follows. In Section 2 we introduce a
mathematical model for the Th cells-macrophages interactions and
discuss the long-term behaviour of the model by investigating the
number and stability of the steady states. We also investigate numeri-
cally the dynamics of this model, and discuss the conditions under
which the model displays a type-I or a type-II immune response. In
Section 3 we generalise the previous model to incorporate also tumour
dynamics. Again, we calculate the steady states and their stability to
emphasise the complexity of the new model. We also investigate
numerically the short-term and long-term dynamics of the model for
tumour-immune interactions, and discuss the parameter values for
which we see tumour elimination in the presence of a type-I immune
response and in the presence of a type-II immune response. We
conclude in Section 3.3 with a summary and discussion of the results.
2. Modelling the Th1&Th2 and M1&M2 interactions
We ﬁrst ignore the presence of the tumour, and investigate the
dynamics of the interactions between the Th cells and macrophages,
following their cross-talk (via cytokines, which we consider implicitly).
Thus we deﬁne four variables: the density of Th1 cells (H1), the density
of Th2 cells (H2), the density of M1 macrophages (M1) and the density
of M2 macrophages (M2). The time-evolution of these variables is given
by
⎛
⎝⎜
⎞
⎠⎟
dH
dt
a M p HM H H
m
e H= + 1 − + − ,H H H
1
1 1 1
1 2
1
11 1 1 (1a)
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The following assumptions are incorporated in Eqs. (1):
• The Th1 cells are activated at a rate aH1 in the presence of IFN-γ
cytokines that can be produced by M1 macrophages (Preuße et al.,
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Fig. 3. Graphical description of the possible interactions between M1/M2 macrophages,
Th1/Th2 cells and tumour cells, via type-I cytokines (e.g. IFN γ− ) and type-II cytokines
(e.g. IL −4, IL −13).
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2012). These cells grow at a rate pH1 in the presence of type-I
cytokines such as IL −2 (Taylor-Robinson, 1997) or IL −12 (His
et al., 1993) (which can be also produced by M1 macrophages), up to
maximum carrying capacity m1. The growth term also incorporates
the competition between the Th1 and Th2 cells for antigens
(Magombedze et al., 2014). Note that high Th2 responses lead to a
suppression of Th1 responses and vice-versa, as observed experi-
mentally (Magombedze et al., 2014). The natural death rate of Th1
cells is eH1 (Magombedze et al., 2014).
• The Th2 cells are activated at a rate aH2 in the presence of IL −4 and
IL −13 cytokines that can be produced by M2 macrophages
(Romagnani, 1999). Moreover, the Th2 cells grow at a rate pH2 in
the presence of IL −4 (Zhu et al., 2002), up to maximum carrying
capacity m1. The natural death rate of Th2 cells is eH2 (Magombedze
et al., 2014).
• The M1 macrophages are activated at a rate aM1 in the presence of
IFN γ− cytokine, produced also by Th1 cells (Preuße et al., 2012;
Weisser et al., 2013). Also, the M1 cells grow at a rate pM1 via a self
renewal process (Helming, 2011), up to a maximum carrying
capacity m2. The apoptosis rate of M1 cells is eM1 (Gauthier et al.,
2013). Note that M1 macrophages can become M2 macrophages, in
the presence of type-II cytokines (Allavena and Mantovani, 2012).
We denote by rM1 the re-polarisation rate from M1 to M2 macro-
phages (Wang et al., 2012).
• The M2 macrophages are activated at a rate aM2 in the presence of IL
−4, IL −13 (which can be produced by Th2 cells) (Weisser et al.,
2013). Moreover, the M2 cells proliferate in the presence of IL −4
cytokines characteristic to a Th2-environment (Jenkins et al., 2011)
(hence the proliferation rate p HM 22 ), up to a maximum carrying
capacity of m2 cells. (Note that, in contrast to the M2 cells, the M1
cells proliferate via self-renewal (Helming, 2011), and thus we do
not multiply the pM1 rate with the H1 variable.) The apoptosis rate of
M2 cells is eM2 (Gauthier et al., 2013). Finally, since the M2
macrophages can change their phenotype and become M1 macro-
phages in the presence of type-I cytokines (Allavena and Mantovani,
2012), we denote by rM2 the re-polarisation rate from M2 to M1 cells
(Wang et al., 2012).
We note here that there are a few studies that suggest the possibility of
Th1 ↔ Th2 re-polarisation based on the environment (Panzer et al.,
2011). However, since this concept of Th re-polarisation is still new, we
will not investigate it in this study.
A non-dimensionalised version of the model (1) is shown in
Appendix C. However, throughout this study we prefer to work with
this dimensional model since in the next two sections we will discuss
some of the results in the context of dimensional experimental studies.
Moreover, the non-dimensionalisation approach does not reduce
signiﬁcantly the number of model parameters.
2.1. Steady state and stability
Before investigating the long-term behaviour of model (1), we
mention that this system has non-negative solutions provided that the
initial data are also non-negative (see the discussion in Appendix B). A
ﬁrst step in analysing the long-term dynamics of (1) is to focus on the
steady states. The analysis illustrates two types of equilibria:
1. No immune cells: H H M M( *, *, *, *) = (0, 0, 0, 0)1 2 1 2 . For the parameter
values used throughout this study (see Table A.1, and the discussion
in Appendix E), the eigenvalues of the Jacobian matrix associated
with system (1) are negative at this steady states (see Fig. E.16 in
Appendix E). Thus, for these parameter values, this immune-free
state is stable. A more general discussion about the conditions on the
parameter values that allow for stable or unstable zero states can be
found in Appendix E.
2. All immune cells present: H H M M H H M M( , , , ) = ( *, *, *, *)1 2 1 2 1 2 1 2 . There
are two such equilibrium points, where the states H*1 , H*2 , M*1 and M*2
are given implicitly by the following equations:
⎛
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M
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1
,H
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1
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For the parameter values chosen in Table A.1, Fig. 4 shows that there
are two non-zero steady states (and simple linear stability analysis
indicates that one state is stable while the other state is unstable - see
Fig. E.16 in Appendix E). Moreover, for the parameter values used
here, we observe that M M* > *1 2 , and correspondingly H H* > *1 2 (see
also the caption of Fig. 4 for the exact steady state values). This
corresponds to a type-I immune response that dominates the
dynamics of model (1).
To investigate the possibility of having also other types of immune
responses that dominate the dynamics (i.e., a type-II response where
M M* < *1 2 and H H* < *1 2 ; or a mixed type-I/type-II response where, for
example, M M* > *1 2 but H H* < *1 2 ) in Fig. 5 we present a bifurcation
diagram for the ratio of M M*/ *1 2 and H H*/ *1 2 steady states (given by Eqs.
(2)), as we vary: (a) the ratio of macrophages re-polarisation rates
(r r/M M1 2) versus the ratio of activation rates for the Th1 and Th2 cells
(a a/H H1 2), and (b) the ratio of macrophages re-polarisation rates (r r/M M1 2)
versus the ratio of macrophage activation rates (a a/M M1 2). When we vary
a a/H H1 2 in panel (a), we notice that we can have:
• a type-I immune response at the overlap between the red (gray on
black/white print) surfaces, when r r/ ≫ 1M M1 2 and a a/ ≤ 1H H1 2 ;
• a type-II immune response (at the overlap between the blue
surfaces) when r r/ ≪ 1M M1 2 ;
• a mixed type-I/type-II immune response when r r/ ≥ 1M M1 2 and
a a/ ⪡1H H1 2 .
When we vary a a/M M1 2 in panel (b), we notice that we can have either a
type-I or a type-II immune response (since the curves for M M*/ *1 2 and
H H*/ *1 2 overlap). Details of how we created these bifurcation diagrams
are presented in Appendix D.
2.2. Short- and long-term immune dynamics
To investigate numerically the transient and long-term dynamics of
macrophages and Th cells, we use the parameter values described in
Table A.1. We assume that antigen is discovered at time t=0 by the M1
macrophages (which are the primary host defence (Mills and Ley,
2014)). So, the initial values for these simulations are: M (0) = 1001 ,
M (0) = 02 , H (0) = 01 and H (0) = 02 .
In Fig. 6 we consider the case a a/ = 0.125 ≪ 1H H1 2 , which leads to an
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immune response characterised by H H* < *1 2 (since the activation and
growth of H1 and H2 cells depends on the magnitudes of aH1 and aH2;
see also equations (1a) and (1b)). Fig. 6(a) illustrates the dynamics of
model (1), when we consider r r/ = 1.8 > 1M M1 2 and thus M M* > *1 2 (a
mixed type-I/type-II immune response, as predicted by the bifurcation
diagram in Fig. 5(a)). In regard to the transient immune dynamics:
during the ﬁrst 19 days the Th2 response is lower than the Th1
response, but after day 19 the Th1 response becomes lower than the
Table A.1
Table summarising the parameters that appear in models (1) and (3), and their values used throughout the numerical simulations. References marked by “*” correspond to parameter
values that were approximated based on experimental studies. Some of the elements in column “Value” show not only the speciﬁc values used for the simulations, but also the parameter
ranges (in parentheses) over which we varied those parameters.
Param. Description Value Units Ref
α tumour growth rate 0.69 − 0.97 1/day *Danciu et al. (2013)
β carrying capacity of the tumour 109 cell Eftimie et al. (2010),de Pillis et al.
(2005)
f tumour natural death rate 10−8 1/day Estimate
gH1 killing rate of tumour cells by the Th1 cells 5×10
−9-10−7 1/day Estimate
gH2 killing rate of tumour cells by the Th2 cells 10−9 (10 − 10−9 −7) 1/day Estimate
gM1 killing rate of tumour cells by M1 macrophages 6×10
−9 1/((cell)
(day))
Estimate
gM2 tumour growth rate in the presence of M2 cells 2.3 × 10−10, 7.3 × 10−10
(10 − 7.3 × 10−10 −9)
1/((cell)
(day))
Estimate
nH1 inactivation rate of Th1 cells by tumour cells 10
−7 1/((cell)
(day))
Eftimie et al. (2010)
nH2 inactivation rate of Th2 cells by tumour cells 10
−7 1/((cell)
(day))
Eftimie et al. (2010)
nM1 inactivation rate of M1 cells by tumour cells 10−7 (10 − 7 × 10 )−7 −4 1/((cell)
(day))
Estimate
nM2 recruitment rate of M2 cells in the presence of tumour cells 10−7 (10 − 10 )−10 −7 1/((cell)
(day))
Estimate
aH1 activation rate of Th1 cells 0.001–0.008 1/day Estimate
aH2 activation rate of Th2 cells 0.001–0.008 1/day Estimate
aM1 activation rate of M1 cells 0.001 1/day Estimate
(10 − 10 )−4 −2
aM2 activation rate of M2 cells 0.001 1/day Estimate
(10 − 10 )−4 −2
m1 carrying capacity of Th cells 10
8 1/cell Eftimie et al. (2010)
m2 carrying capacity of macrophages 10
9 1/cell * Lee et al. (1985)
pH1 interaction rate between Th1 cells and type−1 cytokines produced by the
M1 cells, which leads to the proliferation of Th1 cells
0.09 (0.009 − 0.17) 1/(day)
(cell)
Estimate
pH2 interaction rate between Th2 cells and type−2 cytokines produced by the
M2 cells, which leads to the proliferation of Th2 cells
0.09 (0.009 − 0.17) 1/(day)
(cell)
Estimate
pM1 proliferation rate of M1 cells 0.02 (10 , 10 )−3 −1 1/day Estimate
pM2 interaction rate between M2 cells and the IL−4 cytokines produced by Th2
cells, which leads to M2 proliferation
0.02 1/(day)
(cell)
* Jenkins et al. (2011)
rM1 M1 → M2 transition rate 0.05–0.09 1/day Wang et al. (2012)
rM2 M2 → M1 transition rate 0.05–0.08 1/ day Wang et al. (2012)
eH1 death rate of the Th1 cells 0.03 1/day Magombedze et al. (2014)
eH2 death rate of the Th2 cells 0.03 1/day Magombedze et al. (2014)
eM1 death rate of the M1 cells 0.02 1/day Magombedze et al. (2014)
eM2 death rate of the M2 cells 0.02 1/day Magombedze et al. (2014)
(H1*,H2*,M1*,M2*)
dM2/dt=0
is obtained from eq.
and H2=H2(M1,M2)
dM1/dt=0
is obtained from eq.
 H1=H1(M1,M2)
where:
dH1/dt=0
dH2/dt=0
(i)
(ii)
(ii)
(i)
Fig. 4. Steady states H H M M( *, *, *, *)1 2 1 2 for system (1), as shown by the ﬁlled circles marking the intersection of nullclines dH dt/ = 01 and dH dt/ = 02 . We emphasise that to graph these
curves, we ﬁrst solved dM dt dM dt/ = / = 01 2 for H1 and H2 as functions ofM1 andM2, and then substituted the expressions for H M M( , )1 1 2 and H M M( , )2 1 2 into the equations for dH dt/ = 01
and dH dt/ = 02 . Despite the apparent overlap between the continuous curve for dH dt/ = 01 and the dotted curve for dH dt/ = 02 , there are actually only two intersection points (see ﬁgures
on the right): (i) M* = 0.3241 , M* ≈ 0.1752 , H* = 3.0591 , H* = 0.0982 , and (ii) M* = 5.176 × 101 8, M* ≈ 4.824 × 102 8, H* = 5.066 × 101 7, H* = 4.934 × 102 7.
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Th2 response. The large initial Th1 response leads to a large M1
response. Nevertheless, on day 5, the M2 response becomes larger than
the M1 response. Around day 25, there is a second switch between the
magnitudes of the M1 and M2 responses. Fig. 6(b) illustrates the long-
term dynamics of macrophages and Th cells for r r/ = 0.625 < 1M M1 2 . In
this case, the level of M2 macrophages stays higher than the level of M1
macrophages even during transient times (see panel (b)(i) for
t ∈ (5, 30); compare this with panel (a)(i) where M M>1 2 for t > 25).
Asymptotically, the solution approaches a steady state with H H* < *1 2
and M M* < *1 2 (a type-II immune response, as predicted by the
bifurcation diagram in Fig. 5(a)).
In Fig. 7 we consider the case a a/ ≫ 1H H1 2 , which leads to an
immune response characterised by H H* > *1 2 . Fig. 7(a) illustrates the
dynamics of model (1), when r r/ = 1.8 > 1M M1 2 and the long-term
dynamics is dominated by a type-I immune response (as predicted by
the bifurcation diagram in Fig. 5(a)). In regard to the transient
dynamics, as before we observe a double switch in the magnitude of
macrophages response. Fig. 7(b) illustrates the dynamics of model (1)
for r r/ = 0.625 < 1M M1 2 . The solution approaches a steady state with
H H* > *1 2 and M M* < *1 2 (i.e., a mixed type-I/type-II immune response,
Fig. 5. Bifurcation diagram for the ratio of M M*/ *1 2 and H H*/ *1 2 steady states (given by Eqs. (2)), as we change the ratio of: (a) r r/M M1 2 versus a a/H H1 2; (b) r r/M M1 2 versus a a/M M1 2. The black
surface describes the parameter region where M M*/ * < 11 2 or H H*/ * < 11 2 , while the red surface (gray on black/white print) describes the parameter region where M M*/ * > 11 2 or H H*/ * > 11 2 .
Note that for panel (b), the surfaces for H H*/ *1 2 and M M*/ *1 2 coincide. A type-I immune response occurs when the red (gray on black/white print) surfaces overlap in each of the panels in
(a) and (b). A type-II immune response occurs when the black surfaces overlap in each of the panels (a) and (b). (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
Fig. 6. Dynamics of model (1) for a a= 0.001 < = 0.008H H1 2 (which leads to H H* < *1 2 ). (a) Short-term dynamics (panel (i)) and long-term dynamics (panel (ii)) obtained when
r = 0.09M1 , r = 0.05M2 . b) Short-term dynamics (panel (i)) and long-term dynamics (panel (ii)) when r = 0.05M1 , r = 0.08M2 . For the rest of parameter values see Table A.1.
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as predicted by the bifurcation diagram in Fig. 5(a)).
Note in Figs. 6 and 7 that there are points where the curves have
non-continuous derivatives. This is likely a numerical artefact, the
result of the number of points used to plot the curves and the scale of
the plot.
We conclude that the dynamics of model (1) can be dominated by a
type-I, a type-II or a mixed type-I/type-II immune responses, depend-
ing on the ratio r r/M M1 2 and the activation rate of immune cells. Note
that for these simulations, we also varied the macrophages activation
rates (a a,M M1 2) within the interval (10 , 10 )
−4 −2 , but the overall dynamics
did not change. We acknowledge that model dynamics might change if
we would vary some of the ﬁxed parameters (i.e., those parameters for
which we found values in the literature; see Table A.1).
3. Modelling the Th1&Th2 and M1&M2 interactions with
tumour cells
Next, we investigate the anti-tumour and pro-tumour eﬀects of M1/
M2 macrophages and Th1/Th2 cells. Thus, we consider ﬁve variables:
the density of tumour cells (T), the density of Th1 cells (H1), the density
of Th2 cells (H2), the density of M1 macrophages (M1) and the density
of M2 macrophages (M2). The time-evolution of these variables is given
by
⎛
⎝⎜
⎞
⎠⎟
dT
dt
αT T
β
fT g HT g H T g MT g M T= 1 − − − − − + ,H H M M1 2 1 21 2 1 2 (3a)
⎛
⎝⎜
⎞
⎠⎟
dH
dt
a M p HM H H
m
n HT e H= + 1 − + − − ,H H H H
1
1 1 1
1 2
1
1 11 1 1 1 (3b)
⎛
⎝⎜
⎞
⎠⎟
dH
dt
a M p H M H H
m
n H T e H= + 1 − + − − ,H H H H
2
2 2 2
1 2
1
2 22 2 2 2 (3c)
⎛
⎝⎜
⎞
⎠⎟
dM
dt
a H p M M M
m
n MT e M r M r M= + 1 − + − − + − ,M M M M M M
1
1 1
1 2
2
1 1 2 11 1 1 1 1 2
(3d)
⎛
⎝⎜
⎞
⎠⎟
dM
dt
a H p M H M M
m
n M T e M r M
r M
= + 1 − + + − −
+ .
M M M M M
M
2
2 2 2
1 2
2
2 2 2
1
2 2 2 2 1
2 (3e)
In addition to the assumptions incorporated in model (1), for model (3)
we make also the following assumptions:
• Tumour cells grow at a rate α, up to a carrying capacity β (which is
chosen to correspond to the maximum tumour size allowed for
experimental protocols in mice (NIH, 1996)). To model the phe-
nomenological observation that tumour growth slows down as
tumour becomes very large and depletes the available nutrients
(Laird, 1964), we choose logistic growth. Tumour cells have a very
low natural death (i.e., apoptosis) rate f (Wong, 2011). The Th1 cells
kill the cancer cells at a rate gH1 (via IL −2 and IFN γ− ); see Knutson
and Disis (2005). Moreover, the tumour cells can be killed by the
Th2 cells at a rate gH2 (via IL −4 & IL −13 cytokines that attract
eosinophils (Mattes et al., 2003)). Also, M1 macrophages kill
tumour cells at a rate gM1 (through the release of tumouricidal
products such as NO (Zhang et al., 2014; Lamagna et al., 2006).
Finally, the presence of M2 macrophages increases the proliferation
of cancer cells (Sica et al., 2008). We denote by gM2 the proliferation
rate of cancer cells in the presence of M2 cells. For simplicity, we
Fig. 7. Dynamics of model (1) for a a= 0.008 > = 0.001H H1 2 (which leads to H H* > *1 2 ). (a) Short-term dynamics (panel (i)) and long-term dynamics (panel (ii)) obtained when
r = 0.09M1 , r = 0.05M2 ; b) Short-term dynamics (panel (i)) and long-term dynamics (panel (ii)) obtained when r = 0.05M1 , r = 0.08M2 . For the rest of parameter values see Table A.1.
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assumed that all immune cells interact with tumour cells in a linear
manner. Under this assumption, the term modelling tumour pro-
liferation can be written as T α g M αT β( + − / )M 22 , suggesting that the
presence of M2 cells can increase the maximum tumour size. This
seems to be conﬁrmed by experimental studies showing that
tumours co-inoculated with M2 macrophages grow much larger
than control tumours (see, for example, Fig. 5 in Yamaguchi et al.
(2016)).
• The Th1 cells can be inactivated by the tumour cells at a rate nH1
(Magombedze et al., 2014; Eftimie et al., 2010). All other rates that
control the dynamics of Th1 cells are as described in Section 2.
• The Th2 cells can be inactivated by the tumour cells at a rate nH2
(Magombedze et al., 2014). All other rates that control the dynamics
of Th2 cells are as described in Section 2.
• The anti-tumour M1 cell population can be reduced, at a rate nM1, by
the tumour cells that secrete pro-tumour cytokines (e.g., IL −10,
TGF-β) (Mantovani et al., 2008). All other rates that control the
dynamics of M1 macrophages are as described in Section 2.
• The recruitment of M2 cells at the tumour site is helped by cytokines
(e.g., IL −10) and chemokines (e.g., CCL2) produced by the tumour
cells (Solinas et al., 2009). We denote this recruitment rate by nM2.
For simplicity, throughout this study we consider n n=M M2 1. All
other rates that control the dynamics of M2 macrophages are as
described in Section 2.
We emphasise that in model (3), we incorporated only an example of
tumour-macrophage-Th cell interactions. Continuous development of
this research area, will likely reveal more types of interactions among
these cells. However, it is not the goal of this article to model detailed
dynamics of tumour-immune interactions. Rather, we plan to investi-
gate whether the assumptions incorporated in (3) can explain the
paradoxical anti-tumour and pro-tumour immune dynamics observed
experimentally in B16 melanoma cells (as discussed in Section 1).
We also note that while there are many other types of tumour
growth laws (e.g., exponential, power, von Bertalanﬀy, Gompertz or
sub-linear) that can ﬁt various experimental data sets, recent studies
suggest that the most appropriate growth laws seem to be dependent
on the details of the experiments and on the particular tumour cell lines
(Murphy et al., 2016; Sarapata and de Pillis, 2014; Benzekry et al.,
2014; Talkington and Durrett, 2015). Since the goal of this study is not
to compare in detail our results to various experimental data sets, we
decided to focus only on one law, the logistic growth, and to investigate
whether this assumption on tumour growth can help propose some
generic biological mechanisms that can explain the apparent paradox
in the observed anti-tumour immune responses.
Before investigating the dynamics of system (3), we note that (3)
has non-negative solutions (see the discussion in Appendix B).
3.1. Steady states and stability
Next, we study the long-term behaviour of model (3), when the
system is at equilibrium. The existence of four possible equilibrium
points (listed below) emphasises the complexity of (3).
1. No tumour cells and no immune cells: T H H( *, *, *,1 2
M M*, *) = (0, 0, 0, 0, 0)1 2 .
2. No immune cells, but tumour cells present:
T H H M M T( *, *, *, *, *) = ( *, 0, 0, 0, 0)1 2 1 2 , with T β f α* = (1 − / ).
3. No tumour cells and all immune cells present:
T H H M M H H M M( *, *, *, *, *) = (0, *, *, *, *)1 2 1 2 1 2 1 2 where H*1 , H*2 , M*1 and
M*2 are described in Section 2.1. As before, there are two such states.
4. Presence of all immune and tumour cells: T H H M M( *, *, *, *, *)1 2 1 2 ,
where T*, H*1 , H*2 , M*1 and M*2 are given implicitly by the following
equations:
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟T β
g H g H g M g M f
α
* = 1 −
* + * + * − * +
,H H M M1 2 1 21 2 1 2
(4a)
⎛
⎝⎜
⎞
⎠⎟
M
n H T e H
a p H H H
m
* =
* * + *
+ * 1 −
* + *
1
,H H
H H
1
1 1
1
1 2
1 1
1 1 (4b)
H
n M e M r M r M p M M M
m
a
* =
* + * + * − * − *(1 −
* + *)
,
M M M M M
M
1
1 1 1 2 1
2 1
2
1 1 2 1 1
1
(4c)
⎛
⎝⎜
⎞
⎠⎟
M
n H T e H
a p H H H
m
* =
* * + *
+ * 1 −
* + *
1
,H H
H H
2
2 2
2
1 2
2 2
2 2 (4d)
H
e M r M r M n M
a p M M M
m
* =
* + * − * − *
+ *(1 −
* + *)
.M M M M
M M
2
2 2 1 2
2
2 1
2
2 1 2 2
2 2 (4e)
For the parameter values shown in Table A.1, there are three such
steady states that are real and positive (see Fig. E.18 in Appendix E),
and their stability is illustrated in Fig. E.19(e)–(g).
As in Section 2.1, we are now interested in investigating the
parameter space where tumour growth and elimination occurs in the
presence of a type-I immune response, a type-II response or a mixed
response. Thus, we focus on the two steady states with non-zero
immune responses. Since the steady state H H M M(0, *, *, *, *)1 2 1 2 is
similar to the state investigated in Fig. 5, we can conclude that
tumour elimination can occur in the presence of a type-I response, a
type-II response, or a mixed type-I/type-II response. We will return
to this aspect in Section 3.2, when we will investigate numerically the
long-term dynamics of system (3).
For the tumour-immune coexistence state T H H M M( *, *, *, *, *)1 2 1 2 ,
let us ﬁrst investigate the parameter values for which T* > 0, which is
equivalent (from (4a)) with solving the following equation for T* > 0:
α T α
β
f g H g H g M g M− * − − * − * − * + * = 0.H H M M1 2 1 21 2 1 2 (5)
Note in Eqs. (4c)–(4e) that H*1,2 can be expressed in terms of M*1,2. In
addition, we can make the assumption that M M m* + * ≈1 2 2 (assump-
tion supported by the numerical results; see Figs. 10–12). This
allows us to re-write the condition for the existence of the state
T* > 0 as
⎛
⎝⎜
⎞
⎠⎟
α
β
T α f
g a M
n T e M
g a m
n T e M
g m m
M
g m
M
* = − −
( )
( + )(1 + )
−
( * + )(1 + )
− −
1 +
+
1 +
,
H H m
H H
H H
H H
M
M
2
2
2 2
1 1 2
1 1
2 2
2 2
1
2
(6)
where M M M= */ *1 2 . We graph this equation in Figs. 8 (for lower gM1:
g = 6 × 10M
−9
1
) and Fig. 9 (for higher gM1: g = 6 × 10M
−8
1
), to study
the changes in the parameter space where T* > 0, as we vary gM2, gH1
and gH2.
In Fig. 8, we notice that for low gM2 values (see panels (a), (a');
where g = 2.3 × 10M
−10
2
), the existence of a tumour-immune coex-
istence state requires M M M= */ * ≪ 11 2 and H H H= */ * ≪ 11 2 , which is
equivalent to a type-II immune response. Increasing gM2 (see panels
(b), (b'); where gM2 is increased 30 times, to g = 6.9 × 10M
−9
2
) can
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increase the values of the ratio M M*/ *1 2 for which T* > 0 can exist.
These results suggest that, for the gM2 values investigated in this
study (panels (a), (a')), whenever tumours grow they are accompa-
nied by a type-II immune response. However, for very large gM2
values, tumours can exist also for M > 1 and H > 1 (see panels (b),
(b')). This result suggests that there could be fewer M2 cells
compared to M1 cells, but if these cells secrete large amounts of
type-II cytokines, they can skew the tumour microenvironment in
favour of tumour sustenance and growth. (We will return to this
hypothesis in the Discussion section.) We also need to emphasise
here that an increase in gH1 (from 4.2 × 10
−9 in panels (a), (b), to
1.26 × 10−7 in panels (a'), (b')) reduces the parameter space over
which we can expect tumour-growth in the presence of a type-I
response.
In Fig. 9 we notice that the 10-fold increase in gM1 (from
g = 6 × 10M
−9
1
in Fig. 8 to g = 6 × 10M
−8
1
here) has two main eﬀects:
(i) forces T* > 0 to exist mainly during a type-II response, and (ii)
induces the requirement for much higher gM2 values for tumour
persistence in the presence of a type-I response (i.e., at least a 150-
fold increase in gM2; see panels (b), (b'), where only a mixed type-I/
type-II response was obtained after a 126-fold increase in gM2). We
emphasise here that small changes in gH2 do not have a signiﬁcant
eﬀect on tumour growth (also supported by the sensitivity analysis in
Fig. 14). To observe a diﬀerence between the diagrams in panels (a),
(b) and those in panels (a'), (b') we had to increase gH2 by more than
40-fold (shown in panels (a'), (b') is the eﬀect of a 60-fold increase in
gH2). In this case, the increase in gH2 aﬀected mainly the region where
Fig. 8. Parameter space where a tumour-immune coexistence steady state with T* > 0 can exist. Here we show tumour size T* vs. aH vs. M M M= */ *1 2 or H H H= */ *1 2 , as we vary gM2
(increased 30-fold from 2.3 × 10−10 to 6.9 × 10−9) and gH1 (increased 30-fold from 4.2 × 10−9 to 1.26 × 10−7): (a) g = 2.3 × 10M2
−10, g = 4.2 × 10H1
−9; (b) g = 6.9 × 10M2
−9,
g = 4.2 × 10H1
−9; (a') g = 2.3 × 10M2
−10, g = 4.2 × 30 × 10 = 1.26 × 10H1
−9 −7; (b') g = 6.9 × 10M2
−9, g = 4.2 × 30 × 10 = 1.26 × 10H1
−9 −7. Here we chose g = 1 × 10H2
−9, g = 6 × 10M1
−9,
a = 0.001H2 and vary aH1 in the ratio a a a= /H H H1 2. The rest of parameter values are as in Table A.1.
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H H H= */ * > 11 2 (see the right ﬁgures in panels (b), (b')).
Overall, Figs. 8 and 9 suggest that the parameters most likely to
impact tumour growth/decay are gH1, gM2 and gM1. We will return to
this aspect in Section 3.3, when we will perform a sensitivity analysis
for the transient dynamics of model (3).
3.2. Short-term and long-term dynamics
To investigate numerically the long-term dynamics of immune cells
and cancer cells, we use the parameter values described in Table A.1.
We chose to use the same parameter values as in Section 2.2, to
investigate the eﬀect of introducing a tumour on the interactions
between Th cells and macrophages. The initial values for our simula-
tions are: T (0) = 105, M (0) = 1001 , M (0) = 02 , H (0) = 01 and H (0) = 02 . As
before, we chose M (0) > 01 since the M1 macrophages are the primary
host defence (Mills and Ley, 2014).
Tumour elimination. First, we focus on the parameter ranges for
rM1 and rM2 that ensure tumour elimination in the presence of a type-
I immune response, a type-II immune response, or a combination of
both type-I/type-II immune responses. In this case, the dynamics will
approach the stable steady state H H M M(0, *, *, *, *)1 2 1 2 , and the dominant
immune responses are consistent with those in the bifurcation diagram
shown in Fig. 5. We emphasise this aspect by discussing separately the
following two cases involving the activation rates a a,H H1 2 for the Th1
and Th2 cells:
(1) Case a a<H H1 2. Fig. 10 illustrates the short-term dynamics (panels
(i); t < 30 days) and long-term dynamics (panels (ii); t ≤ 100 days)
Fig. 9. Parameter space where a tumour-immune coexistence steady state with T* > 0 can exist. Here we show tumour size T* vs. aH vs. M M M= */ *1 2 or H H H= */ *1 2 , for g = 6 × 10M1
−8
and diﬀerent parameter values for gM2 (increased 126-fold from 2.3 × 10
−10 to 2.9 × 10−8) and gH2 (increased 60-fold from 1×10
−9 to 6×10−8): (a) g = 2.3 × 10M2
−10, g = 10H2
−9; (b)
g = 2.9 × 10M2
−8, g = 10H2
−9; (a') g = 2.3 × 10M2
−10, g = 6 × 10H2
−8; (b') g = 6.9 × 10M2
−9, g = 6 × 10H2
−8. Here we chose g = 4.2 × 10H1
−9, a = 0.001H2 and vary aH1 in the ratio
a a a= /H H H1 2. The rest of parameter values are as in Table A.1.
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of model (3), for two diﬀerent cases: (a) r r/ = 1.8 ≫ 1M M1 2 , and (b)
r r/ = 0.625M M1 2 . In panel (a)(i) we observe a double switch between
the M1 and M2 cells that dominate the dynamics (and this is
associated with only one switch in the Th1-Th2 dynamics). In
panel (b)(i) we observe a single switch the dynamics of both M1
and M2 cells, and Th1 and Th2 cells. In all cases the tumour is
eliminated, and the results are consistent with the bifurcation
diagrams in Fig. 5(a).
(2) Case a a>H H1 2. Fig. 11 illustrates the short-term dynamics (panels
(i)) and long-term dynamics (panels (ii)) of model (3) for two
cases: (a) r r/ = 1.8M M1 2 , (b) r r/ = 0.625M M1 2 . In panel (a)(i) we observe
a double switch between the M1 and M2 cells that dominate the
dynamics (but this is not associated with any switch in the Th1-
Th2 dynamics). In panel (b)(i) we observe a double switch between
the Th1 and Th2 cells that dominate the dynamics (associated with
a single switch in the M1-M2 dynamics).
Tumour persistence. Fig. 12(a) shows tumour growth for r r/ = 1M M1 2
(and g = 4.2 × 10H
−9
1
, g = 7.3 × 10M
−10
2
). In the long term, the dynamics
of system (3) approaches the stable steady state (T H H M M*, *, *, *, *1 2 1 2 ).
By investigating the short-term dynamics of model (3) (see panel a(i))
we observe a switch in both the Th1-Th2 and M1-M2 dynamics, from
an initial type-I response to a later type-II response. This is consistent
with the bifurcation results in Fig. 8(b), where tumour exists for
M H, ≪ 1 (where M M M= */ *1 2 , H H H= */ *1 2 ). Moreover, we would like to
emphasise that the dormant behaviour exhibited by the tumour for
t ∈ (5, 15) is mainly the result of a very large M1 population that keeps
the tumour under control. As soon as this M1 population is reduced,
the tumour grows fast towards its carrying capacity.
The diﬀerence between tumour dormancy/growth in Fig. 12 and
tumour elimination in Figs. 10 –11 is the result of (a) a small change in
the rate at which tumour cells are eliminated by the Th1 cells via the
cytokines they produce (from g = 4.4 × 10H
−9
1
for tumour elimination
to g = 4.2 × 10H
−9
1
for tumour growth), and (b) a small change in the
rate at which M2 macrophages can support tumour growth (from
g = 2.3 × 10M
−10
2
for tumour elimination to g = 7.3 × 10M
−10
2
for tu-
mour growth). However, diﬀerent other combinations of parameter
changes can lead to similar tumour dormant behaviours (which seem to
be controlled by relatively high levels of M1 cells). To investigate the
eﬀect of small changes in parameter values on the level of tumour and
immune cells during dormancy (not only M1 but also M2, Th1 and Th2
cells), in Section 3.3 we will perform a sensitivity analysis.
In Section 1 we mentioned the experimental results in Chen et al.
(2011) (see also Fig. 2(c)), which showed tumour growth being
associated with a shift in the ratio of M1 and M2 cells: from M1:M2
≈ 90:10 on day 7, to M1:M2 ≈ 20:80 on day 14. To compare these
experimental results with our numerical results, in Fig. 12(b) we show
the percentage of Th cells and macrophages on day 4.5 (when tumour
is small), day 14 (when tumour is dormant) and day 19 (when tumour
approaches its carrying capacity). We see that tumour growth is not
only associated with an increase in the percentage of M2 cells (as
shown experimentally in Chen et al. (2011)), but also with an increase
in the percentage of Th2 cells (as shown experimentally in Protti and
Monte (2012)). Note that this is one possible outcome of the model.
Changes in parameter values could lead to diﬀerent ratios of Th2:Th1
cells and M2:M1 cells as tumour progresses.
Finally, we recall that the results in Fig. 8(b) suggested that by
increasing gM2 one could observe tumour existence also in the case of a
Fig. 10. Dynamics of model (3), when a a= 0.001 < = 0.008H H1 2 and the tumour is eliminated. For this case, we always have H H* < *1 2 . (a) Short-term dynamics (panel (i)) and long
term dynamics (panel (ii)) when r = 0.09M1 , r = 0.05M2 . (b) Short-term dynamics (panel (i)) and long-term dynamics (panel (ii) for r = 0.05M1 , r = 0.08M2 . For these simulations we also
choose: g = 4.8 × 10H1
−9, g = 2.3 × 10M2
−10, α = 0.69. For the rest parameters values see Table A.1.
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type-I immune response with M H, > 1 (in addition to a type-II
response, with M H, < 1). We show in Fig. 13 the short-term and
long-term dynamics of model (3), characterised by the persistence of
tumour cells at lower values (with a maximum of about 5×107 cells).
This persistence is the result of a type-I immune response, which
alternates for short periods of time with a type-II response. We
emphasise that these oscillations in tumour growth/decay (triggered
by oscillations in the type-I/type-II immune responses) might not be
always observable in a clinical setting. Friberg and Mattson (1997)
showed that in humans, the tumour diagnostic level is between 107 and
109 cells. Therefore, 5×107 cells might not be always detected clinically.
3.3. Sensitivity analysis
Since the majority of parameter values could not be approximated
from the literature, in the following we perform a sensitivity analysis to
investigate the eﬀect of changes in these parameters on the growth of
the tumour. To this end, we vary each parameter P by ±10% or ±90% at
a time (i.e., P P± ▵ , with P P▵ = 0.1 or P P▵ = 0.9 ), and investigate the
impact of this change on tumour size on day 10 (an arbitrarily-chosen
day, when the tumour has not reached its maximum size yet). The
relative change in tumour size on day 10 (i.e., T▵ (10)) is used in Fig. 14
to plot the ratio of relative changes: ( )/( )TT
P
P
▵ (10)
(10)
|▵ |
| | .
Fig. 14 illustrates tumour sensitivity to changes in the parameter
values: (a) by ±10% and (b) by ±90%. The parameters that have the
most signiﬁcant eﬀect on tumour size when varied by ±10% are: the
tumour growth rate (α), the proliferation of Th1 cells (pH1), the
elimination rate of tumour cells by the Th1 cells (gH1) and by M1
macrophages (gM1), the carrying capacity of Th cells (m1), the carrying
capacity of macrophages (m2), the transition rate from M1 to M2 cells
(rM1), the activation rate of M1 cells (aM1) and the proliferation of M2
cells in the presence of type-II cytokines (pM2). It is likely that pM1 might
also have higher impact on tumour if we would consider higher self-
proliferation rates for M1 cells. The parameters that have the most
signiﬁcant impact on tumour size when varied by ±90% are pH1 and α
(similar to case (a)). Also a decrease in m1, gH1, gM1 and rM1 leads to a
signiﬁcant increases in tumour size (see the inset in the right panel of
Fig. 14(b)). (Note that, in Fig. 14(b) is diﬃcult to see the reduction in
tumour size as we vary the parameter values – because of the very large
increases in tumour size.) We also need to emphasise that gH2 and gM2
(both associated with a type-II immune response) do not have a
signiﬁcant impact on tumour reduction. This is a particularly interest-
ing result that might be of biological interest, since at least gH2 has the
same order of magnitude – see Table A.1 – as parameters gH1 and gM1
(which have a signiﬁcant eﬀect on tumour reduction/growth).
Moreover, this result supports the idea that the elimination of tumour
cells by the Th2 cells in Mattes et al. (2003) was not the result of direct
Th2-tumour interactions (via Th2-cytokines), but the combined eﬀect
of diﬀerent anti-tumour cells.
To gain a better understanding on tumour dormancy (and on the
role of immune response in controlling tumour growth), next we
perform a tumour and immune sensitivity to small changes in four
parameter values associated with anti-tumour/pro-tumour immune
responses: gH1, gH2, gM1, gM2. To this end, we start with the baseline
parameters that lead to tumour dormancy/growth in Fig. 12(a), and we
vary them by ±10% to investigate the changes in tumour and immune
sizes at day t=10 (when dormancy occurs). First, we note that during
tumour dormancy, changes in parameter gH1 have a slightly bigger
Fig. 11. Dynamics of model (3) when a a= 0.008 > = 0.001H H1 2 and the tumour is eliminated. For this case, we always have H H* > *1 2 . (a) Short-term dynamics (panel (i)) and long-term
dynamics (panel (ii)) for r = 0.09M1 , r = 0.05M2 . (b) Short-term dynamics (panel (i)) and long-term dynamics (panel (ii)) for r = 0.05M1 , r = 0.08M2 . For these simulations we also choose
g = 4.8 × 10H1
−9, g = 2.3 × 10M2
−10, α = 0.69. For the rest of parameters values see Table A.1.
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impact on tumour at day t=10 (T (10)) compared to changes in
parameter gM1 - see Fig. 15(a). This is in contrast to the case of tumour
elimination (see Fig. 14(a), left panel) where gM1 has a bigger impact on
T (10) compared to gH1. Second, we note that during tumour dormancy
gM2 has a stronger impact on T (10) (see Fig. 15(a)) compared to the case
of tumour elimination where gM2 barely aﬀects T (10) (see Fig. 14(a)). In
fact, we observe that ±10% changes in the three parameters gH1, gM1 and
gM2, lead to changes of relatively similar magnitudes in tumour cells
(Fig. 15(a)), and in each of the four types of immune cells (Figs. 15(b)-
(d)). This suggest that tumour dormancy is the result of a delicate
balance between the anti-tumour eﬀect of Th1 and M1 cells, and the
pro-tumour eﬀect of M2 cells. Moreover, by looking at panels (b)-(e) we
observe that the eﬀects of gM1 and gM2 do not balance perfectly during
dormancy: gM2 causes slightly larger eﬀects in both tumour and
immune responses compared to gM1 (and this imbalance eventually
translates into tumour relapse).
To conclude the discussion on the eﬀects of parameters gH1, gM1 and
gM2 on the immune responses during tumour dormancy, we stress that
while it was expected that an increase in gM1 and gH1 would be associated
with an increase in M1 and H1 (through the direct reduction of
tumour), it was however unexpected that gH1 would have an eﬀect on
H2 and M2 cells (stronger than the eﬀects of parameters gH2 and gM2).
Fig. 12. (a) Tumour growth exhibited by model (3), when a a= = 0.008H H1 2 and r = 0.09M1 , r = 0.05M2 . Note that tumour growth is associated with a type-II immune response: M M* < *1 2
and H H* < *1 2 . (i) short-term dynamics (t < 25; the y-axis is shown on a log-scale); (ii) long-term dynamics. Here we choose: g = 4.2 × 10H1
−9, g = 7.3 × 10M2
−10, α = 0.69. For the rest of
parameters values see Table A.1. (b) Percentage of Th cells and macrophages calculated on 3 diﬀerent days (t=4.5, t=14, t=19), for the numerical simulations shown in (a).
Fig. 13. Short-term dynamics (panel (a)) and long-term dynamics (panel (b)) of model (3), when g = 7.3 × 10M2
−9, g = 8.546835 × 10H2
−9, a a= 0.08⪢ = 0.001H H1 2 , r r= 0.09⪢ = 0.0051 2 .
For the rest parameters values see Table A.1. In this case, the tumour persists being controlled alternatively by a type-I and a type-II immune response.
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4. Summary and discussion
In this article, we derived two mathematical models for the
dynamics of immune responses involving Th1 & Th2 and M1&M2
cells, in the absence and in the presence of tumour cells. We then used
these models to propose mechanistic hypotheses that could explain the
contradictory results in the experimental data for the immune response
against melanoma B16 cells.
We started with a model that considered only the interplay between
M1 and M2 macrophages, and Th1 and Th2 cells in response to some
external pathogen that ﬁrst triggered an M1 response (i.e., M (0) > 01 ).
To shed light on the complexity of model dynamics, we ﬁrst calculated
the steady states (to study the long-term behaviour of the model) and
then we performed numerical simulations for the short-term and long-
term model dynamics. By focusing on the ratio r r/M M1 2 (of macrophages
re-polarisation rates), and the activation rates of Th cells (aH1, aH2) in
the presence of signals received from macrophages, we were able to
classify the immune responses into: a type-I dominated response
(H H>1 2, M M>1 2), a type-II dominated response (H H<1 2, M M<1 2),
or a combination of type-I and type-II responses (e.g., M M>1 2 but
H H<1 2); see the results in Figs. 6, 7. Note that experimental studies
have shown that diﬀerent diseases associated with the Th1 and Th2
immune responses can show diﬀerent levels of M1 and M2 macro-
phages. For example, in Barros et al. (2013) (Table 1), the authors
showed that about 60.7% of Th1 disease cases investigated (in the
context of infectious mononucleosis and Crohn's disease) have
M1>M2, and about 72.5% of Th2 disease cases investigated (in the
context of allergic nasal polyps, oxyuriasis, wound healing and foreign
body granulomas) have M2 > M1. Thus their results suggest that there
are Th1 diseases with a higher level of M2 cells, and Th2 diseases with
a higher level of M1 cells (consistent with our numerical results).
Next, we generalised the mathematical model to consider also
tumour dynamics. We showed numerically that tumour elimination can
occur both in the presence of a type-I dominated immune response, as
well as in the presence of a type-II dominated response (as observed
experimentally in Mattes et al. (2003), Xie et al. (2010), Kpbayashi
et al. (1998); see also Figs. 1 and 2). We need to emphasise that tumour
elimination also required a relatively large tumour lysis rates gH1 and
gM1 and a low gM2. As before, the type of immune response that
dominated the dynamics was decided by the ratio r r/M M1 2 and the
activation level of immune cells (aH1, aH2).
Tumour growth towards carrying capacity (or some very large size)
was always associated in our study with a long-term type-II immune
response, i.e., H H>2 1, M M>2 1; see Fig. 12. In this case, the initial type-
I response (with M M>1 2 for t ≤ 5 days and H H>1 2 for t ≤ 10 days) was
always replaced in the long-term by a type-II immune response. This
shift from a type-I to a type-II response was observed also experimen-
tally in the context of cancer growth. For example, Chen et al. (2011)
showed a 90:10 ratio of M1:M2 macrophages in B16F10 melanoma
tumours around day 7, and a 20:80 ratio of M1:M2 macrophages
around day 14 (see Fig. 2(c)). Other experimental studies have
described a shift from a Th1 response to a Th2 response during the
ﬁrst 14–20 days of progression of malignant tumours (see Tatsumi
et al., 2002 for human melanoma). These experimental studies also
suggested that one could improve cancer outcome by re-polarising the
macrophages and Th cells from a type-II response associated with
tumour growth to a type-I response associated with tumour decay
(Heusinkveld and van der Burg, 2011). Our theoretical results are in
agreement with the experimental suggestion that a type-I response
improves long-term cancer outcome. Moreover, our results also
emphasise the complexity of the tumour-immune system, in which a
type-I immune response might alternate with a type-II immune
response (for short-term or long-term), thus leading only to tumour
control but not tumour elimination.
We stress that the interaction between the pro-tumour/anti-tumour
eﬀects of macrophages and Th cells aﬀects tumour dynamics in a
nonlinear manner. For example, a 10-fold increase in the rate of
tumour clearance by M1 macrophages (gM1) caused tumour persistence
only in the presence of a type-II immune response (i.e., a type-I
immune response would be associated to tumour clearance). To ensure
tumour persistence also in the presence of a type-I response, the 10-
fold increase in gM1 needed to be counter-balanced by at least a 150-fold
increase in the tumour growth rate in the presence of M2 cells, gM2 (see
Figs. 8 and 9). This nonlinearity in the anti-tumour response is likely
the result of the interplay between the macrophages and the Th cells,
an aspect not very well studied at experimental level. Although there
Fig. 14. Sensitivity analysis for model (3), when each model parameter is increased (red bars) and decreased (cyan bars) by: (a) 10% and (b) 90%. Here, we show the relative changes in
tumour size on day t=10 in response to the changes in the parameter P values: T T P P(▵ (10)/ (10))/(|▵ |/| |), with the negative values showing the decrease in tumour size, and the positive
values showing the increase in tumour size. The baseline parameters are those shown in Table A.1. The inset ﬁgures in panel (b) show the details of the sensitivity analysis for the
parameters that do not lead to the two largest changes in tumour size (i.e., after we remove pH1 and α from the bar plots). (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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are some studies on the interactions between macrophages and CD4+ T
cells, for example, in the context of breast and lung cancer (DeNardo
et al., 2009; Almatroodi et al., 2016), or in the context of rheumatoid
arthritis (Roberts et al., 2015), such studies do not shed much light on
the nonlinear interactions between these diﬀerent types of immune
cells.
In the context of the anti-tumour eﬀect of macrophages, the
sensitivity analysis in Fig. 14(a) suggested that tumour elimination
was mainly the eﬀect of M1 macrophages (and to a lesser extent the
eﬀect of Th1 cells). This is an interesting hypothesis generated by the
model, which, if validated experimentally, could inﬂuence the current
anti-tumour immune therapies that focus mainly on T cell responses
(Wang et al., 2014; Voena and Chiarle, 2016). In contrast, the
sensitivity analysis in Fig. 15 suggested that the transient decrease in
tumour size on day 10 during tumour dormancy was mainly the eﬀect
of Th1 cells (and to a lesser extent the eﬀect of M1 cells). In fact, the
tumour dormant behaviour was the result of a delicate balance between
the anti-tumour responses of Th1 and M1 cells, and the pro-tumour
responses of M2 cells. In addition, the results in Figs. 8 and 9 suggested
that the three parameters, gH1, gM1 and gM2, inﬂuenced also the
asymptotic behaviour of model (3). This is in support of the idea that
anti-cancer immunotherapies should focus on the combined eﬀect of T
cells and M1 macrophages.
The results in Fig. 8 suggested that there could be very few M2 cells
(and many M1 and Th1 cells), but if these M2 cells secrete large
amounts of type-II cytokines (i.e., large gM2), they can skew the tumour
microenvironment in favour of tumour sustenance and growth. This
would support the experimental results in Mattes et al. (2003), where a
type-I environment was not enough to eliminate B16F10 melanoma
cells. The authors in Mattes et al. (2003) recognised that the inability of
Th1 cells to eradicate tumours might have been inﬂuenced by the
presence of pro-angiogenic tumour-inﬁltrating macrophages (i.e., M2
cells), but they did not measure the levels of M2 and M1 macrophages,
nor the levels of Th1 and Th2 cells. In fact, Mattes et al. (2003)
identiﬁed the Th1 and Th2 immune responses by the levels of type-I
and type-II cytokines produced by these cells: high IL-5, IL-13 and IL-
4 for a Th2-dominated response, and high IFN-γ, TNF-α and IL-13 for
a Th1-dominated response (note here the relatively high levels of IL-13
observed during both Th1 and Th2 responses; and the fact that IL-13 is
also involved in the alternative activation of M2 macrophages
(Martinez and Gordon, 2014)). Since many experimental studies focus
on the levels of cytokines as a proxy for the number of immune cells
corresponding to a type-I or type-II response (Mattes et al., 2003;
Almatroodi et al., 2016), to be able to test our hypothesis regarding the
role of gH2 and M2 cells on tumour persistence during type-I responses,
we need to extend model (3) by incorporating explicitly the eﬀects of
type-I and type-II cytokines on tumour-immune interactions (i.e., an
approach similar to Eftimie et al. (2010), where a mathematical models
Fig. 15. Sensitivity analysis of the tumour and immune responses for model (3), during tumour dormancy. We focus on four model parameters (gH1, gH2, gM1, gM2), and increase them
(red bars) and decrease them (cyan bars) by 10%. We also show the relative changes in tumour size and all four immune cells on day t=10 in response to the changes in the parameter P
values: M M P P(▵ (10)/ (10))/(|▵ |/| |)i i and H H P P(▵ (10)/ (10))/(|▵ |/| |)i i , for i=1,2: (a) Relative change in T (10); (b) Relative change in H (10)1 ; (c) Relative change in H (10)2 ; (d) Relative change in
M (10)1 ; (e) Relative change in M (10)2 . The baseline parameters are those shown in the caption of Fig. 12. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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incorporated the eﬀects of type-I, type-II, tumour-promoting and
tumour-suppressing cytokines).
In this study, to keep the models relatively simple, we ignored
deliberately the microenvironment which can alter the immune
response against cancer (Hanahan and Weinberg, 2011). However,
the incorporation of the explicit eﬀects of type-I and type-II cytokines
(which can be further altered by the tumour cells (Burkholder et al.,
2014)) would allow us not only to compare our results with available
experimental cytokine data, but also to gain a better understanding of
how to control cell-cell communication (by controlling cytokine
signalling) with the ultimate goal of improving cancer immunothera-
pies.
Note from Table A.1 that models (1) and (3) contain both fast and
slow variables. One could have used a quasi-steady state analysis to
simplify the models. However, such an analysis might lead to limita-
tions in our understanding of the transient dynamics of the Th1-Th2
and M1-M2 cells (see, for example the study in Flach and Schnell
(2006)). This type of transient dynamics was observed in experimental
studies on early tumour behaviours, which suggested that the ratios of
Th1/Th2 cells or M1/M2 cells can be used as independent predictive
markers of patient survival (Monte et al., 2011; Protti and Monte,
2012; Chen et al., 2011). In this theoretical study we showed that these
ratios of immune cells can change once or twice before they stabilise
towards a steady state (and they stabilise when the tumour reaches
either a very large size or is eliminated; see Figs. 10–12). The changes
in the dominating Th or macrophages dynamics are not always
correlated with each other. Moreover, we showed the possibility of
having a long-term oscillatory tumour-immune dynamics characterised
by low tumour values and periodic changes between type-I and type-II
immune responses; see Fig. 13. While sustained periodic tumour
oscillations are not very often observed in clinical studies (although
see Gliozzi et al., 2010), we emphasise that model (3) exhibits such
oscillations for tumour sizes around the detection threshold (of about
10 − 107 8 cells (Friberg and Mattson, 1997)). This suggest that oscilla-
tions between type-I and type-II immune responses (in the presence of
tumour) might be more common in clinical/experimental settings but
they might not be measured since the tumour cannot be detected.
Overall, we hypothesise that trying to predict the long-term outcome of
the tumour while the ratios Th1/Th2 and M1/M2 are still varying due
to the cross-talk with the tumour environment, might not always oﬀer
accurate predictions on patient survival.
At a more theoretical level, it would be interesting to investigate the
diﬀerences between the double feedback in tumour-immune dynamics
modelled in this study, and a single feedback for tumour-immune
interactions. Such an investigation (to be the subject of a future study)
would allow us to uncover the minimal biological mechanisms that
need to be incorporated into a model to explain the dominant type-I
and/or type-II immune responses associated with cancer immu-
notherapies.
Finally, these numerical results for systems (1) and (3) have
generated two new mathematical questions that will be answered
analytically in future studies: (i) analytical investigation of fast and
slow parameters that control transient and long-term tumour-immune
behaviours, and how the simpliﬁed dynamics in the slow/fast models
matches the original dynamics; (ii) analytical investigation of the Hopf
bifurcation that generated the limit cycle shown in Fig. 13.
Biological realism of the parameter values and overall results. The
results of this study depend on the parameter values described in Table
A.1. Some of these values were taken from the literature, others were
approximated based on published experimental results, and the
remaining values were varied within some estimated ranges (see
Appendix A). This approach is very common in the mathematical
immunology literature, due to a lack of quantitative results regarding
the immune responses following various antigen stimulations. In
addition to the fact that very few labs measure and estimate kinetic
parameters (the majority of such studies focusing on lymphocyte
kinetics following pathogen stimulation; see for example Borghans
and Boer, 2007; Asquith et al., 2009; Boer and Perelson, 2013), there is
also the diﬃculty of interpreting kinetic data; see the review in Boer
and Perelson (2013). Moreover, the few rigorously estimated kinetic
parameters in the mathematical immunology literature depend on the
estimation method used, as emphasised in Laydon et al. (1675). A
more detailed discussion on model validation and parameter estima-
tion in mathematical immunology can be found in Eftimie et al. (2016).
Based on these facts, we acknowledge that the majority of models in
the mathematical immunology literature, including this particular
study, can have at this moment only a theoretical value. In particular,
the model presented here can only propose hypotheses regarding the
possible outcomes of the interactions between the Th1-Th2 and M1-
M2 immune responses, in the absence/presence of tumour cells.
We showed that small variations in the values of parameters that
control tumour cells lysis via anti-tumour cytokines (e.g., gH1, gM1, gM2),
or the parameters for the activation of Th cells (a a,H H1 2), or the
macrophages re-polarisation rates (r r,M M1 2) could explain the variety of
tumour-immune dynamics observed in the experimental literature. To
obtain a better understanding of immune responses to speciﬁc
diseases, the next step would be to quantify the rates that control
various type-I and type-II immune responses. Therefore, for a better
mechanistic understanding of the in vivo immune responses, which can
be obtained with a more realistic in silico model, mathematicians (and
immunologists) need to have access to relevant experimental data that
could then be used to parametrise the mathematical models. The goal
of our present study was not to parametrise the models to speciﬁc
diseases, but to propose some general hypotheses regarding the
processes involved in diﬀerent immune responses.
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Appendix A. Parameter values
In Table A.1 we summarise the parameter values used throughout this theoretical study. Some of these values were taken directly from existent
mathematical literature, while other values were approximated based on experimental studies (marked by “*” in Table A.1); see also the discussion
below. However, there were a few parameters for which we could not ﬁnd any values, so we had to provide estimates for them. Some of these
estimates were varied within speciﬁed ranges (see Table A.1).
Next, we discuss the parameter values we approximated using experimental studies, and the values taken from the literature (especially if
diﬀerent mathematical studies used diﬀerent parameter values).
• Danciu et al. (2013) have shown that melanoma cells have a doubling time between 17.2 h and 24 h, which corresponds to a tumour growth rate
of 0.69 − 0.97. For simplicity, throughout this study we choose α = 0.69/day.
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• The proliferation of Th1 and Th2 cells occurs in the presence of type-1 and type-2 cytokines produced by the cells themselves and by the
macrophages in the environment. For simplicity (and since we could not ﬁnd data on the interactions between cytokines and cells; i.e.,
interaction radii, concentration of molecules that lead to cell proliferation), we assume that: (i) the concentrations of type-1 and type-2 cytokines
are directly proportional to the density of M1 and M2 cells, and (ii) the interaction rates between cells and cytokines, pH1 and pH2, are the same for
both populations. This assumption is consistent with the approach in Kogan et al. (2013), Eftimie et al. (2010), which consider similar
recruitment rates for the Th1 and Th2 cells, in response to the cytokine environment. Due to a lack of consistent data on the growth of Th1 and
Th2 populations (e.g., Eftimie et al. (2010) assumed a growth rate of 0.09, while Kogan et al. (2013) assumed a growth rate between10 − 102 4), in
this study, we used an estimated interaction rate of p p= = 0.09.H H1 2 Note that in Fig. 14 we performed a sensitivity analysis of model dynamics
to changes in parameter values, and investigated also the eﬀect of variations in pH1 and pH2.
• In regard to macrophages apoptosis rate, Magombedze et al. (2014) used a death rate of 0.02/day. On the other hand Wang et al. (2012) used a
death rate of 0.2/day. However, experimental studies in Gauthier et al. (2013) showed that mice macrophages were cleared within 5-8 days of
induction of inﬂammation, during the resolution stage of inﬂammation. However, since inﬂammation is a critical component of tumour
progression (Cousins and Werb, 2002), and we could not ﬁnd any speciﬁc references regarding the half-life of macrophages inside tumours, we
assumed here that the death rate of tumour macrophages is much lower than in Wang et al. (2012), and more similar to the value in Magombedze
et al. (2014): e e= = 0.02/dayM M1 2 .
• In regard to the proliferation of macrophages, Jenkins et al. (2011) showed that by treating M2 macrophages with 5 μg of IL-4 and 25 μg anti-IL-
4 antibody (to extend the half-life of the cytokine), it leads to an increased proliferation of macrophages 4 days later (from 1 × 106 in the control
case to about 4.2 × 106 in the IL-4 case). We can approximate the interaction rate between M2 macrophages and the IL-4 cytokine concentration
(produced by Th2 cells) as p g= ln(4.2)/(4 × 30μ ) = 0.012M2 . Assuming only g5μ of IL-4, it leads to p g= ln(4.2)/(4 × 5μ ) = 0.072M2 . Throughout
this study we consider an average of p = 0.02M2 (obtained assuming g17.5 μ of IL-4 in the system). For the self-proliferation rate of M1
macrophages, we could not ﬁnd any data. For simplicity, throughout the simulations we used an average value p = 0.02M1 . Nevertheless, in
Fig. 14 we also investigated the sensitivity of tumour growth in response to changing p ∈ (0.002, 0.038)M1 .
• In Lee et al. (1985) it was suggested that a conservative estimate for the total number of macrophages in a normal adult mouse would be greater
than 1 × 108. Therefore, we have chosen the macrophages carrying capacity to be m = 102 9.
• In the mathematical literature there are various estimations for tumour natural death rate. For example, Wang et al. (2015) estimated a value of
2.08 × 10 /day−6 , while Wodarz et al. (2004) used arbitrary units and estimated tumour death rate at 0.1. On the other hand, Moore and Li (2004)
considered a tumour cell death rate within the range (0,0.8)/day. Since apoptosis is inactivated in cancer cells (Brown and Attardi, 2005), in this
study, we use an estimated value of natural death rate for cancer cells of f = 10 /day−8 .
• In regard to the tumour killing rates by Th1 and Th2 cells (via the cytokines they produce), we note that Hung et al. (1998) incubated 106 B16
melanoma cells with CD4 T cells. The maximum tumour lysis was 30%, obtained at an eﬀector: target ratio of about 32:1. This corresponds to a
tumour killing rate of g g, = 5.3 × 10H H1 2
−8 (den Breems and Eftimie, 2016). Throughout this study, we investigate what happens with the
dynamics of model (3) when we vary g g, ∈ (10 , 10 )H H1 2
−9 −7 .
• Various mathematical studies that investigated macrophages dynamics considered an activation rate within the range (0.0-1.0)/day, depending
on the concentration of type-I and type-II cytokines that trigger their activation (Wigginton and Kirschner, 2001; Wang et al. (2012)). However,
the activation of M1 macrophages is reduced in the presence of type-II cytokines such as IL-10 (Wigginton and Kirschner, 2001), and the
activation of M2 macrophages is reduced in the presence of type-I cytokines such as IFN-γ (Wang et al., 2012). Since the tumour environment
contains both type-I and type-II cytokines, throughout this study we consider lower estimates for the macrophages activation rates:
a a, = 0.001M M1 2 .
Appendix B. Non-negative solutions
Here, we show that system (3) has non-negative solutions. Since (3) is a generalisation of (1), the results hold also for model (1).
To start, we assume that T H H M M(0), (0), , (0), (0) ≥ 01 2 1 2 . Note that if T (0) = 0, M (0) = 01 , M (0) = 02 , H (0) = 01 , H (0) = 02 , then the system is at
equilibrium and the only solution is the trivial one.
Assume that it is possible to have negative solutions. Then there exists a time t < ∞0 deﬁned as
t t T t H t H t M t M t= inf { > 0| ( ) < 0, ( ) < 0, ( ) < 0, ( ) < 0, or ( ) < 0}.0 1 2 1 2 (B.1)
We have the following inequalities:
• From Eq. (3a):
dT
dt
T f g H g H g M g M t t≥ − ( + + + − ), for ≤ .H H M M1 2 1 2 01 2 1 2 (B.2)
Since T t( ) ≥ 00 , there exists a non-negative solution T t T t e( ) ≥ ( ) ∫ f g H g H g M g M ds0 − ( + + + − )H H M M1 1 2 2 1 1 2 2 ≥0, for t t t∈ ( − ϵ , + ϵ ).0 1 0 1
• From Eq. (3b):
dH
dt
H n T e t t≥ − ( + ), for ≤ .H H1 1 01 1 (B.3)
Since H t( ) ≥ 01 0 , there exists a non-negative solution H t H t e( ) ≥ ( ) ≥ 0∫ n T e ds1 1 0 − ( + )H H1 1 , for t t t∈ ( − ϵ , + ϵ )0 2 0 2 .
• From Eq. (3c):
dH
dt
H n e t t≥ − ( + ), for ≤ .H H2 2 02 2 (B.4)
Since H t( ) ≥ 02 0 , there exists a non-negative solution H t H t e( ) ≥ ( ) ≥ 0∫ n T e ds2 2 0 − ( + )H H2 2 , for t t t∈ ( − ϵ , + ϵ )0 3 0 3 .
• From Eq. (3d):
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dM
dt
M n T e r t t≥ − ( + + ), for ≤ .M M M1 1 01 1 2 (B.5)
Since M t( ) ≥ 01 0 , there exists a non-negative solution M t M t e( ) ≥ ( ) ≥ 0∫ n T e r ds1 1 0 − ( + + )M M M1 1 2 , for t t t∈ ( − ϵ , + ϵ ).0 4 0 4
• From Eq. (3e):
dM
dt
M n T e r t t≥ ( − − ), for ≤ .M M M2 2 02 2 1 (B.6)
Since M (0) ≥ 02 , there exists a non-negative solution M t M t e( ) ≥ ( ) ≥ 0∫ n T e r ds2 2 0 ( − − )M M M2 2 1 , for t t t∈ ( − ϵ , + ϵ )0 5 0 5 .
Therefore, the solution T H H M M( , , , , )1 2 1 2 of system (3) is nonnegative for t t t∈ [ , + ϵ)0 0 , with ϵ = min{ϵ , ϵ , ϵ , ϵ , ϵ }1 2 3 4 5 , which contradicts the initial
assumption on t0. Therefore, the solution remains non-negative for all time.
Appendix C. Model non-dimensionalisation
In the following, we present the non-dimensional versions of model (3) (since model (3) is a generalisation of model (1), we choose not to
present also the non-dimensional version of (1)). Consider the following scaling for the variables and parameters that appear in these two models:
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After dropping the bar for simplicity, we obtain the following equations for the time-evolution of variables describing the tumour and immune cells
(i.e., the non-dimensional version of model (3)):
dT
dt
f T T f HT f H T f MT f M T f T= (1 − ) − − − + − ,1 2 1 3 2 4 1 5 2 6 (C.1a)
dH
dt
M b HM H H n HT e H= + (1 − − ) − − ,1 1 1 1 1 1 2 1 1 1 1 (C.1b)
dH
dt
a M b H M H H n H T e H= + (1 − − ) − − ,2 1 2 2 2 2 1 2 2 2 2 2 (C.1c)
dM
dt
a H b M M M n MT e M rM r M= + (1 − − ) − − + − ,1 2 1 3 1 1 2 3 1 3 1 1 2 2 1 (C.1d)
dM
dt
a H b M H M M n M T e M rM r M= + (1 − − ) + − − + .2 3 2 4 2 2 1 2 4 2 4 2 1 2 2 1 (C.1e)
Since this non-dimensionalisation approach did not lead to a signiﬁcant reduction in model parameters (i.e., the 31 parameters in model (3), were
reduced to 25 parameters in model (C.1)), we prefer to work with the original dimensional model. Moreover, while a sensitivity analysis could be
performed on the non-dimensional parameters shown above, such an analysis would not shed light on the eﬀect of original parameters/rates on
tumour growth (especially since parameters such as m1 and m2 - important for the sensitivity of the original model - enter in various combination
terms that form the non-dimensional parameters).
Appendix D. Bifurcation diagrams for the dominant immune responses
Consider the ratios of the steady states M M*/ *1 2 and H H*/ *1 2 given by (2):
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Numerical simulations show that, at the steady state, M M m* + * ≈1 2 2 and H H m* + * ≈1 2 1 (see also Figs. 6 and 7). In this case, the previous two
ratios reduce to
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Solving the ﬁrst equation in (D.3) for H H M M a a e e*/ * = ( */ *)( / )( / )H H H H1 2 1 2 1 2 2 1 , and substituting this term into the second equation in (D.3), denoting by
M M M* = */ *1 2 , r r r= /M M M1 2 and a a a= /H H H1 2, leads to the following second order equation in M*:
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If we ﬁx rM2 and vary rM1, we can graph implicitly M* versus rM versus aH (or aM), as shown in Fig. 5.
Consider now model (3). The case of the tumour-free steady state follows the previous case, and the changes in the immune response as we vary
a a/H H1 2 or r r/H H1 2 can be described again by Fig. 5.
Now, we focus on the steady state (4), and discuss the parameter range where this tumour-present state exists. We look for solutions T* > 0 of
α T α
β
f g H g H g M g M− * − − * − * − * + * = 0.H H M M1 2 1 21 2 1 2 (D.5)
Using (4b)–(4d), we can replace H*1 and H*2 by M*1 , M*2 and T*. Again we make the assumption that M M m* + * ≈1 2 2, H H m* + * ≈1 2 1, as seen
numerically for the steady state dynamics of these models (see also Figs. 10 and 11). Finally, re-writing M*1,2 in terms of m2 and M M M* = */ *1 2 we
obtain the implicit Eq. (6), whose solution was graphed in Fig. 8(a)–(c) (left panels) for diﬀerent values of gM2 versus M
*. One could also graph gM2
versus H H H* = */ *1 2 (right panels in Fig. 8), by considering the relation between the ratio of Th1 and Th2 cells in the presence of tumour cells:
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Appendix E. Jacobian matrix for the immune and tumour-immune systems
The Jacobian matrix associated with system (1) is:
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Fig. E.16 shows the stability of the steady states exhibited by model (1) as we vary one parameter. For simplicity, we chose parameter
r ∈ [0.05, 0.09]M1 (but we note that we could have chosen any other parameter). The four symbols in Fig. E.16 show the real parts of the four
eigenvalues corresponding to the Jacobian matrix (E.1). Numerical calculations of the eigenvalues corresponding to the steady state (0, 0, 0, 0)
show that this state is stable for the parameter values shown in Table A.1. In regard to the two immune coexistence steady states (H H M M*, *, *, *1 2 1 2 )
Fig. E.16. Eigenvalues E E1 − 4 of the Jacobian matrix (E.1) calculated at 3 diﬀerent steady states: (a) Zero state (0, 0, 0, 0);(b) ﬁrst coexistence state (H H M M*, *, *, *1 2 1 2 ); (c) second
coexistence state (H H M M*, *, *, *1 2 1 2 ). Here we assume that a a= = 0.001H H1 2 , r = 0.05M2 and r ∈ [0.05, 0.09]M1 . The rest of parameter values are as described in Table A.1.
R. Eftimie, H. Hamam Journal of Theoretical Biology 420 (2017) 82–104
100
depicted in Fig. 4: the state with low immune response (point (i) on Fig. 4) is unstable, as shown in Fig. E.16(b), and the state with high immune
response (point (ii) on Fig. 4) is stable, as shown in Fig. E.16(c).
We need to emphasise that these stability results depend strongly on all other parameter values listed in Table A.1. As an example, in the
following we show analytically how the stability of the zero state (0, 0, 0, 0) depends on the various parameters in the system. (While such an
analysis could be also performed for all other steady states, it is too complicated and beyond the scope of this paper). The characteristic equation
associated with J λdet( − ) = 0(0,0,0,0) is given by
⎡
⎣⎢
⎤
⎦⎥e λ e λ p e r λ e r λ r r e λ a a p e r λ
a a a a a e λ e r λ F λ
0 = ( − − ) ( − − )( − − − )( − − − ) + ( + )− ( − − − )
+ [ − ( + )( + + )] = ( ).
H H M M M M M M M H H M M M M
H M M H M H M M
1 2 1 1 2 2 1 1 2 2 2 2 1 1 2
1 1 2 2 1 2 2 1
Note that this 4th order polynomial in λ (let us call it F λ( )) can have up to 4 real roots. For λ → ± ∞, we have F λ( ) → ∞. If we can show that there
are parameter values for which, at λ = 0 we have F(0) < 0, then it becomes clear that one root λ must be positive (and thus the zero-state becomes
unstable).
⎡
⎣⎢
⎤
⎦⎥F e e p e r e r r r e a a p e r a a a a a e e r(0) = − ( − )( − − )( − − ) + ( ) − ( − − ) + [ − ( )( + )]H H M M M M M M M H H M M M M H M M H M H M M1 2 1 1 2 2 1 1 2 2 2 2 1 1 2 1 1 2 2 1 2 2 1
It is easy to observe that large rM1, rM2 or pM1 values can all lead to F(0) < 0. Fig. E.17 shows two possible parameter regions where F(0) < 0, thus
ensuring that at least one eigenvalue λ of the Jacobian matrix J (0, 0, 0, 0)1 is positive and the zero state is unstable.
The Jacobian matrix associated with system (3) is:
⎛
⎝
⎜⎜⎜⎜⎜⎜
⎞
⎠
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J
b b b b b
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41 42 43 44 45
51 52 53 54 55 (E.2)
Fig. E.17. Example of parameter regions where the steady state (0, 0, 0, 0) can be unstable (i.e., F(0) < 0). (a) (r p,M M1 1) plane; (b) (r r,M M1 2) plane. All other parameters are kept ﬁxed as
in Table A.1.
Fig. E.18. There tumour-immune coexistence states (T H H M M*, *, *, *, *1 2 1 2 ) exhibited by model (3): (a) values of tumour sizes T*; (b) values of ratios H H*/ *1 2 corresponding to the 3
tumours sizes depicted in (a); (c) values of ratios M M*/ *1 2 corresponding to the 3 tumours sizes depicted in (a). Here we assume that g = 2.3 × 10M2
−10, g = 5 × 10H1
−9, a a= = 0.001H H1 2 ,
r = 0.05M2 and r ∈ [0.05, 0.09]M1 . The rest of parameter values are as described in Table A.1.
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Fig. E.19. The real part of eigenvalues E1-E5 of the Jacobian matrix (E.1) calculated at 3 diﬀerent steady states: (a) Zero state (0, 0, 0, 0, 0);(b) Tumour-present, immune-absent state:
(T β f α* = (1 − / )*, 0, 0, 0, 0); (c), (d) Two tumour-absent, immune-present states: H H M M(0, *, *, *, *)1 2 1 2 ; (e), (f)(g) Three tumour-immune coexistence states: T H H M M( *, *, *, *, *)1 2 1 2 . Here
we assume that g = 2.3 × 10M2
−10, g = 5 × 10H1
−9, a a= = 0.001H H1 2 , r = 0.05M2 and r ∈ [0.05, 0.09]M1 . The rest of parameter values are as described in Table A.1.
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Note that system (3) has: (i) one trivial steady state (0,0,0,0,0); (ii) one tumour-present, immune-absent state (T β βf α* = − / , 0, 0, 0, 0); (iii)
two tumour-absent, immune-present states: H H M M(0, *, *, *, *)1 2 1 2 , similar to those in model (1); (iv) three tumour-present, immune-present states:
T H H M M( *, *, *, *, *)1 2 1 2 . As an example, we illustrate these three tumour-immune coexistence states in Fig. E.18(a), as we vary parameter rM1, while
keeping ﬁxed r = 0.05M2 , a = 0.001H1 , a = 0.001H2 , g = 2.3 × 10M
−10
2
, g = 5 × 10H
−9
1
and all other parameters as in Table A.1. To have a better
understanding of the immune responses during these three tumour sizes, in Figs. E.18(b), (c) we also plot the ratios of H H*/ *1 2 and M M*/ *1 2
corresponding to each of these three coexistence states. Note that for these tumour-immune states, the very low tumour sizes (described by squares
in Fig. E.18(i)) occur in the presence of a type-I immune response (with H H/ > 11 2 in panel (ii), and M M/ > 11 2 in panel (iii)). In contrast, the very
large tumour sizes occur in the presence of a type-II immune response.
Fig. E.19 shows the stability of all steady states exhibited by model (3), (including the coexistence states discussed previously), as we vary
parameter rM1 and keep all other parameters ﬁxed.
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